patent.fyi
Applications  /  US 2026/0355218
United States Patent Application Publication

US 2026/0355218 A1

Published
Nov 12, 2026
Filed
May 7, 2026
Earliest date on the face
May 8, 2025
Classification
A61K 31/5575
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Bimatoprost as the active ingredient

What ifWhat if the drops use bimatoprost as the active ingredient?
Claim language“latanoprostene bunod (LBN)”

An aqueous eye drop contains 0.01% w/v bimatoprost dissolved in a buffered vehicle. Bimatoprost increases aqueous humor outflow and lowers intraocular pressure.

1.2Water as the continuous phase

What ifWhat if the oil phase is dispersed in an aqueous vehicle?
Claim language“liquid vehicle of semifluorinated alkanes”

A high-pressure homogenizer disperses medium-chain triglyceride oil in buffered water, and polysorbate 80 stabilizes the droplets. The oil droplets carry the dissolved active ingredient and distribute it across the tear film after instillation.

1.3Sterile aqueous unit doses

What ifWhat if the formulation contains water and comes in sealed single-use containers?
Claim language“is water-free”

An aqueous buffer forms the continuous phase of an emulsion whose oil droplets carry the active ingredient. Aseptic filling into sterile unit-dose containers and an intact seal maintain sterility through storage, and each container is discarded after opening.

1.4Solid ocular insert

What ifWhat if a solid insert in the lower conjunctival sac delivers the active ingredient?
Claim language“a solution, an emulsion, or a suspension”

A solid ethylene-vinyl acetate matrix contains the active ingredient and fits between the lower eyelid and the eye. The active ingredient diffuses from the matrix into the tear film.

1.5Lower triglyceride concentration

What ifWhat if the formulation contains 5% w/v medium-chain triglyceride oil?
Claim language“10% w/v to 50% w/v”

The formulation contains 5 g of triglyceride oil per 100 mL of finished liquid. The triglyceride and semifluorinated alkane act as a mixed solvent, with the active concentration set below its measured solubility in that blend over the storage temperature range.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Carrier testing on synthetic corneas

An optical test bench uses a curved hydrogel coupon to represent a hydrated corneal surface. A calibrated dispenser places a drop of the water-free latanoprostene bunod, medium-chain triglyceride, and semifluorinated alkane formulation at the center of the coupon. An overhead camera records the drop footprint over time, and image analysis calculates the wetted area and the rate of spreading.

Component substitution

Castor oil as the oil phase

Pharmaceutical-grade castor oil replaces medium-chain triglycerides as the oil phase, and the semifluorinated alkane remains the liquid vehicle. The mixer first combines latanoprostene bunod with castor oil, then disperses that concentrate into the liquid vehicle under controlled agitation. Microscopy tracks droplet size, and samples drawn from the top, middle, and bottom of the vessel measure drug distribution after mixing and holding.

Parameter or scale variation

Metered drops at three volumes

Three interchangeable metering chambers dispense nominal volumes of 8, 12, and 16 microliters from the same water-free oil and semifluorinated alkane formulation. A positive-displacement piston empties each chamber through a common nozzle geometry. A balance measures the mass of 30 individual drops per chamber, and the measured formulation density converts each mass to volume.

Combination with existing systems

Integration with a unit dose filler

A closed feed vessel supplies the formulation to an aseptic form-fill-seal line that produces twist-open single-dose containers. The line forms each container, meters the formulation into it, and seals the opening during the same production cycle. Fill-mass measurements verify the dispensing setting, and vacuum-decay testing checks the integrity of the sealed containers.

Automated or data-driven variant

Raman monitoring of batch composition

A Raman probe in a closed recirculation loop records spectra while the oil phase and semifluorinated alkane mix in the vessel. A multivariate model uses calibration batches with weighed oil and vehicle fractions to estimate the oil fraction from each spectrum. The controller signals the end of mixing when consecutive estimates remain within a predefined tolerance of the batch target.

Automated imaging of phase separation

A temperature-controlled rack holds sealed transparent vials of the formulation upright in front of a fixed camera and diffuse backlight. Software captures an image of each vial at scheduled intervals and locates horizontal intensity transitions below the liquid surface. The system reports the height and growth rate of any separated layer after correcting for the vial background.

Specific version of a part

Latanoprostene bunod at 0.024%

The formulation contains 24 mg of latanoprostene bunod per 100 mL of finished liquid. The finished liquid contains 0.24 mg of active ingredient per milliliter.

Perfluorohexyloctane with triglyceride oil

Perfluorohexyloctane provides the liquid vehicle. A blend of caprylic and capric triglycerides provides the oil component and contributes to dissolution of the active ingredient.

Sealed anhydrous unit doses

Aseptic filling places the water-free, preservative-free liquid into sterile single-use containers. Container closure integrity testing and sterility testing at shelf-life intervals verify that the sealed packages maintain sterility.

Triglyceride oil at 20%

Each 100 mL of finished formulation contains 20 g of medium-chain triglyceride oil. The formulator weighs the oil, blends it with the liquid vehicle, and adjusts the blend to the final volume.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2022/0031649 A1
Published
Feb 3, 2022
Filed
Sep 10, 2019
Class
A61K 31/23
Document BUS 2023/0330104 A1
Published
Oct 19, 2023
Filed
Apr 12, 2023
Class
A61K 31/5575
Claim 1
Document A
Document B
1.10.006% w/v to 0.121% w/v of latanoprostene bunod (LBN) or a pharmaceutically acceptable salt thereof;
An aspect of the present invention provides a preservative-free ophthalmic pharmaceutical emulsion, comprising: 0.01% w/v to 0.1% w/v latanoprostene bunod or a pharmaceutically acceptable salt thereof, 0.2% w/v to 0.7% w/v an oil, 0.4% w/v to 1.4% w/v a surfactant, and at least one pharmaceutical excipient, wherein the HLB values of the oil and the surfactant are calculated together to form a required hydrophilic-lipophilic balance (rHLB) value in a range from 10 to 16.
B · US 2023/0330104 A1 · ¶ 8
1.2at least one excipient, comprising an oil phase and a liquid vehicle of semifluorinated alkanes (SFAs),
In one or more embodiments, the emulsion in the present invention further contains a pharmaceutically acceptable vehicle comprising at least one pharmaceutical excipient, such as oil, surfactants, emulsifiers, chelating agent, tonicity adjusting agents, buffering agents, pH adjusting agents, viscosity enhancers, co-solvent and other agents that may be used in formulating an ophthalmic composition.
B · US 2023/0330104 A1 · ¶ 38
1.3wherein the composition is microbiologically stable, and is water-free and preservative-free;
The water content of the triacylglycerol is preferably not more than 0.08% by weight of water, more preferably not more than 0.07% by weight, even more preferably not more than 0.05% by weight, in each case based on the total amount of triacylglycerol in the composition.
A · US 2022/0031649 A1 · ¶ 31
The results obtained during the long-term and accelerated stability study demonstrate that the preservative-free ophthalmic pharmaceutical emulsion is stable at both fridge and room temperature.
B · US 2023/0330104 A1 · ¶ 78
1.4wherein the composition is formulated into a solution, an emulsion, or a suspension;
An aspect of the present invention provides a preservative-free ophthalmic pharmaceutical emulsion, comprising: 0.01% w/v to 0.1% w/v latanoprostene bunod or a pharmaceutically acceptable salt thereof, 0.2% w/v to 0.7% w/v an oil, 0.4% w/v to 1.4% w/v a surfactant, and at least one pharmaceutical excipient, wherein the HLB values of the oil and the surfactant are calculated together to form a required hydrophilic-lipophilic balance (rHLB) value in a range from 10 to 16.
B · US 2023/0330104 A1 · ¶ 8
1.5wherein in the excipient, the concentration of the oil phase is 10% w/v to 50% w/v; and
TABLE 1 Compositions Inventive Comparative % by weight 1 2 3 4 5 6 7 8 9 MCT oil 85.0 91.0 95.8 89.6 70.0 70.0 96.0 90.0 95.9 SiO2 15.0 4.0 4.0 — 30.0 — 4.0 — — fumed SiO2 — — — 10.0 — 30.0 — 10.0 — precipitated Ethyl- — 5.0 — — — — — — 5.0 cellulose Distilled — — 0.2 0.4 — — — — water Ratio of MCT 1:0.18 1:0.04 1:0.04 1:0.11 1:0.4 1:0.4 1:0.04 1:0.11 1:0.05 oil to SiO2 Structure shaped shaped gel gel powder powder liquid liquid shaped at 21° C. body body body made of made of
A · US 2022/0031649 A1 · ¶
An aspect of the present invention provides a preservative-free ophthalmic pharmaceutical emulsion, comprising: 0.01% w/v to 0.1% w/v latanoprostene bunod or a pharmaceutically acceptable salt thereof, 0.2% w/v to 0.7% w/v an oil, 0.4% w/v to 1.4% w/v a surfactant, and at least one pharmaceutical excipient, wherein the HLB values of the oil and the surfactant are calculated together to form a required hydrophilic-lipophilic balance (rHLB) value in a range from 10 to 16.
B · US 2023/0330104 A1 · ¶ 8
1.6wherein the oil phase is medium-chain triglyceride (MCT).
The triacylglycerol in the composition according to the invention is preferably a pure medium-chain triacylglycerol, in particular obtained by hydrolysis of coconut oil or palm kernel oil, fractionation of the medium-chain fatty acids, and subsequent esterification with glycerol. Pure medium-chain triacylglycerols are also referred to as neutral fat, MCT oil or MCT fats (medium-chain triglycerides).
A · US 2022/0031649 A1 · ¶ 30
Latanoprostene bunod and castor oil are taken and mixed as an oil phase mixture in a glass beaker, and the mixture is stirred continuously using a dry glass rod until complete solubilization of latanoprost takes place.
B · US 2023/0330104 A1 · ¶ 66

An empty cell means only that no passage was reproduced there.

Statements in these documents
The invention further relates to the use of a composition or of a solid shaped body as an item of equipment for outdoor activities, camping, and/or sports activities, and/or in a diet.
A · US 2022/0031649 A1 · ¶ 1
The invention further relates to the use in the health sector, particularly in therapeutic nutrition for the dietary treatment of various diseases or for weight loss.
A · US 2022/0031649 A1 · ¶ 1
Therefore, there is a need to improve ocular blood flow to treat those glaucoma patients.
B · US 2023/0330104 A1 · ¶ 6
As a result, they found that LBN promote the blood velocity of ONH of the patients with glaucoma, which may prevent glaucoma progression.
B · US 2023/0330104 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355218 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355218/, SHA-256 3cfbd97193afd1ad873ee92c751abbe5c35f567aa375b4c6f6ae75ca42a8a12a
First published
Permanent addresshttps://patent.fyi/US20260355218/
Content fingerprint (SHA-256)3cfbd97193afd1ad873ee92c751abbe5c35f567aa375b4c6f6ae75ca42a8a12a
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi